香港股市 將在 8 小時 28 分鐘 開市

榮昌生物-B (9995.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
113.500-5.300 (-4.46%)
收市價: 4:08PM HKT

榮昌生物-B

58 Middle Beijing Road
Yantai Development Zone Yantai Area of Shandong Pilot Free Trade
Yantai
China
86 53 5611 3513
http://www.remegen.com

版塊Healthcare
行業Biotechnology
全職員工

高階主管

名稱標題支付行使價出生年份
Dr. Jianmin FangExec. Director, CEO & Chief Scientific Officer1962
Dr. Daotian FuPres1962
Mr. Jia LiCFO & Joint Company Sec.1980
Dr. Ruyi HeExec. Director, Chief Medical Officer & Head of Clinical Research1961
Mr. Jian LinExec. Director1955
Ms. Pak Yu Tam A.C.I.S., A.C.S.Joint Company Sec.
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in the People's Republic of China and internationally. The company's products in various stages of development include Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. It is also developing RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; and RC88, which is in Phase 1 clinical trials for use in the treatment of diabetic macular edema, as well as pre-clinical products, such as RC108, RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

公司管治

截至 無 止,榮昌生物-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。